Skip to main content
. 2023 Feb 15;13(6):2483–2509. doi: 10.1016/j.apsb.2023.02.006

Figure 3.

Figure 3

Heart- and liver-on-a-chip device for drug screening. (A) A heart-OAC measuring the responses of CMs to drugs and proving the antiarrhythmic efficacy of verapamil. Reprinted with the permission from Ref. 109. Copyright © 2016 MDPI (Basel, Switzerland). (B) A 3D bioprinted heart-OAC to assess doxorubicin-induced cardiotoxicity based on CM beating rate. Reprinted with the permission from Ref. 111. Copyright © 2016 Elsevier. (C) A liver-OAC demonstrating the hepatoxicity of APFP. Reprinted with the permission from Ref. 113. Copyright © 2016 IOP Publishing Ltd. (D) A liver-OAC recapitulating nonalcoholic steatohepatitis for testing the therapeutic effect of elafibranor. Reprinted with the permission from Ref. 114. Copyright © 2021 Wiley Periodicals LLC.